Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLD
Advanced Science · 2025
DOI: 10.1002/advs.202412903 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Feng Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of Chin…. Hauptthemen laut MEDLINE: Histone Deacetylases, Histone Deacetylase Inhibitors, Fatty Liver. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taishan Scholars Program of Shandong Province, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities-Ocean University of China and the Science Foundation for Excellent Young Scholars of Shandong Province.
Abstract (Originalsprache)
Metabolic dysfunction‐associated steatotic liver disease (MASLD) represents the most prevalent chronic liver disorder globally. Due to its intricate pathogenesis and the current lack of efficacious pharmacological interventions, there is a pressing need to discover novel therapeutic targets and agents for MASLD treatment. Herein, it is found that histone deacetylase 11 (HDAC11), a subtype of HDAC family, is markedly overexpressed in both in vitro and in vivo models of MASLD. Furthermore, the knockdown of HDAC11 is observed to mitigate lipid accumulation in hepatic cells. A highly selective HDAC11 inhibitor, B6 , which exhibits favorable pharmacokinetic property and liver distribution, is further designed and synthesized. Integrating RNA‐seq data with in vivo and in vitro experiments, B6 is found to inhibit de novo lipogenesis (DNL) and promote fatty acid oxidation, thus mitigating hepatic lipid accumulation and pathological symptoms in MASLD mice. Further omics analysis and experiments reveal that B6 enhances the phosphorylation of AMPKα1 at Thr172 through the inhibition of HDAC11, consequently modulating DNL and fatty acid oxidation in the liver. In summary, this study identifies HDAC11 as a potential therapeutic target in MASLD and reports the discovery of a highly selective HDAC11 inhibitor with favorable drug‐like properties for the treatment of MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.
- Key Laboratory of Metabolism and Regulation for Major Diseases of Anhui Higher Education Institutes, Hefei University of Technology, Hefei, 230031, China.
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao, 266003, China.
- Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, SC, 29425, USA.
- Marine Biomedical Research Institute of Qingdao, Qingdao, Shandong, 266071, China.
ORCID-Profile: Feng Zhang, Yajun Duan
Förderung
- Taishan Scholars Program of Shandong Province
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities-Ocean University of China and the Science Foundation for Excellent Young Scholars of Shandong Province
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Zhang, F., Yue, K., Sun, S., Lu, S., Jia, G., Zha, Y., Zhang, S., Chou, C. J., Liao, C., Li, X., & Duan, Y. (2025). Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLD. Advanced Science. https://doi.org/10.1002/advs.202412903
Vancouver
Zhang F, Yue K, Sun S, Lu S, Jia G, Zha Y, et al. Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLD. Advanced Science. 2025. doi:10.1002/advs.202412903
BibTeX
@article{Zhang2025,
author = {Zhang, Feng and Yue, Kairui and Sun, Simin and Lu, Shengyuan and Jia, Geng and Zha, Yang and Zhang, Shuang and Chou, C James and Liao, Chenzhong and Li, Xiaoyang and Duan, Yajun},
title = {Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLD},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202412903}
}
EUVIMED